SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences spurts on reporting 13% rise in Q1 consolidated net profit

18 Aug 2017 Evaluate

Eris Lifesciences is currently trading at Rs. 590.00, up by 7.65 points or 1.31% from its previous closing of Rs. 582.35 on the BSE.

The scrip opened at Rs. 580.00 and has touched a high and low of Rs. 595.00 and Rs. 570.55 respectively. So far 1,13,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 728.00 on 14-July-2017 and a 52 week low of Rs. 510.50 on 11-Aug-2017.

Last one week high and low of the scrip stood at Rs. 606.10 and Rs. 533.25 respectively. The current market cap of the company is Rs. 8,113.19 crore.

The promoters holding in the company stood at 55.93%, while non-institutions held 44.07% stake in the company.

Eris Lifesciences has reported 12.51% jump in its net profit at Rs 69.95 crore for the quarter under review as compared to Rs 62.17 crore for the same quarter in the previous year. However, the total income of the company decreased by 10.67% at Rs 169.35 crore for Q1FY18 as compared Rs 189.57 crore for the corresponding quarter previous year.

On consolidate basis, the company has reported 13.45% rise in its net profit at Rs 70.84 crore for the quarter ended June 30, 2017 as compared to Rs 62.44 crore for the corresponding quarter in the FY17. Total consolidated income of the company increased marginally by 2.39% at Rs 192.07 crore for quarter under review as compared to Rs 187.58 crore for the same quarter in the previous year.

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×